HIV
Conditions
Keywords
HIV Prevention, bnAb, Monoclonal antibody, Intravenous, Triple combination, VRC07-523LS, PGT121.414.LS, PGDM1400LS
Brief summary
HVTN 206/HPTN 114 is a randomized, double blind, controlled, phase 2 clinical trial to evaluate the safety, tolerability, pharmacokinetics, and neutralization of VRC07-523LS, PGT121.414.LS, and PGDM1400LS broadly neutralizing monoclonal antibodies given intravenously in adult participants without HIV. The hypothesis of the study is that the combination of VRC07-523LS and PGT121.414.LS and PGDM1400LS antibodies when administered via the intravenous (IV) route will be safe and tolerable in adult participants without HIV. The study aims to enroll 200 participants across multiple sites with an estimated total duration of participation of eighteen (18) months.
Interventions
BIOLOGICALVRC07-523LS 400mg
Intravenous infusion (IV)
BIOLOGICALPGT121.414.LS 400mg
IV infusion
BIOLOGICALPGDM1400LS 400mg
IV infusion
BIOLOGICALVRC07-523LS 3200mg
IV infusion
BIOLOGICALPGT121.414.LS 1600mg
IV infusion
BIOLOGICALPGDM1400LS 1600mg
IV infusion
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health (NIH)
Department of Health and Human Services
Dale and Betty Bumpers Vaccine Research Center (VRC)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Participants need to be between 18 and 65 years old. * Participants must have access to a participating clinical research site and be willing to follow the study schedule. * Participants should understand the study details and be willing to give informed consent. * Participants must agree not to join any other clinical trials until they finish this study. * Participants must be willing to receive HIV test results. * Participants should be open to discussing HIV prevention. * Clinic staff should assess participants as having a low risk of getting HIV, and participants must commit to avoiding high-risk behaviors during the study. * Hemoglobin: Participant meets minimum levels depending on gender and hormone therapy status. * White Blood Cells (WBC): Should be within the normal range or approved by a site clinician. * Platelets: At least 100,000 cells/mm³. * Alanine aminotransferase (ALT): Less than 5 times the upper normal limit. * Creatinine: Less than 1.8 times the upper normal limit or less than 1.5 times your baseline level. * Participants must test negative for HIV-1 and HIV-2. * Participants urine protein must be negative or trace. Reproductive Status: * Participants of child-bearing potential need a negative pregnancy test within 72 hours before starting the study. * Participants must agree to use effective birth control from at least 21 days before joining the study until the end of the study. * Participants must agree not to try to become pregnant through any method during the study.
Exclusion criteria
* Participants cannot have had a blood transfusion within the last 120 days. * Participants cannot have received experimental treatments within the last 30 days. * Participants cannot weigh less than 35 kg (about 77 lbs). * Participants cannot plan to join another clinical trial during this study. * Participants cannot be pregnant or breastfeeding. * Participants cannot have received an HIV vaccine in a previous trial (unless it was a placebo, subject to Protocol Safety Review Team's approval). * Participants cannot have had any live vaccines within the last 14 days or non-live vaccines within the last 7 days. * Participants cannot have had humanized or human monoclonal antibodies recently, except for certain HIV antibodies more than 12 months ago. * Participants cannot have had allergy shots within the last 14 days. * Participants cannot have taken immunosuppressive drugs within the last 30 days, with some exceptions like nasal sprays or mild skin treatments. * Participants cannot participate if they have had serious allergic reactions to the components of the study product. * Participants cannot have received immunoglobulin within the last 60 days. * Participants cannot have an autoimmune disease that requires immunosuppressive treatment, unless it's mild and stable. * Participants cannot have an immune system deficiency. * Participants cannot have any significant medical condition or abnormal lab results that could impact their health during the study. * Participants cannot have conditions that make repeated injections or blood draws difficult. * Participants cannot have conditions requiring active medical treatment that could pose a risk during the study. * Participants cannot have conditions that could be confused with reactions to the study product. * Participants cannot have medical, social, or occupational conditions that would interfere with the study. * Participants cannot have severe psychiatric conditions, like ongoing risk of suicide or recent history of suicide attempts. * Participants cannot be undergoing treatment for tuberculosis. * Participants cannot have severe asthma that requires frequent medication or emergency care. * Participants cannot have diabetes mellitus (DM) (well-controlled Type 2 DM or an isolated history of gestational diabetes are not exclusionary). * Participants blood pressure must be below 160/110 mmHg. * Participants cannot have any diagnosed bleeding disorders. * Participants cannot have active cancer but may be eligible if, in the investigator's estimation, they have a reasonable assurance of sustained cure, or are unlikely to experience recurrence of malignancy during the period of the study * Participants cannot have had seizures or taken seizure medications in the past 3 years. * Participants cannot have a history of severe allergic reactions like anaphylaxis, unless it has been well-controlled for at least 5 years. * Participants cannot have acute or unstable hepatitis B or C, but stable chronic cases may be considered.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of participants experiencing local Adverse Events (AEs) | At Days 1, 4, 7, 169 and 173 |
| Percentage of participants experiencing local AEs | At Days 1, 4, 7, 169 and 173 |
| Number of participants experiencing systemic AEs | At Days 1, 4, 7, 169 and 173 |
| Percentage of participants experiencing systemic AEs | At Days 1, 4, 7, 169 and 173 |
| Number of participants experiencing unsolicited AEs | Baseline through Week 48 |
| Percentage of participants experiencing unsolicited AEs | Baseline through Week 48 |
| Number of participants experiencing Serious Adverse Events | Baseline through Week 48 |
| Number of participants who discontinue study product administration and terminate the study early | Baseline through Week 48 |
| Percentage of participants who discontinue study product administration and terminate the study early | Baseline through Week 48 |
| Change from baseline in ALT | Baseline, Days 1, 57, 169, 225 and 337 |
| Change from baseline in aspartate aminotransferase (AST) | Baseline, Days 1, 57, 169, 225 and 337 |
| Change from baseline in alkaline phosphatase (Alk Phos) | Baseline, Days 1, 57, 169, 225 and 337 |
| Change from baseline in creatinine | Baseline, Days 1, 57, 169, 225 and 337 |
| Change from baseline in Complete Blood Count (CBC) | Baseline, Days 1, 57, 169, 225 and 337 |
Secondary
| Measure | Time frame |
|---|---|
| Area under the curve (AUC) of VRC07-523LS, PGDM1400LS, and PGT121.414.LS | At Days 1, 4, 7, 29, 57, 169, 225 and 337 |
| Maximum concentration (C(max)) of VRC07-523LS, PGDM1400LS, and PGT121.414.LS | At Days 1, 4, 7, 29, 57, 169, 225 and 337 |
| Time to C(max) (T(max)) of VRC07-523LS, PGDM1400LS, and PGT121.414.LS | At Days 1, 4, 7, 29, 57, 169, 225 and 337 |
| Clearance (CL) of VRC07-523LS, PGDM1400LS, and PGT121.414.LS | At Days 1, 4, 7, 29, 57, 169, 225 and 337 |
| Volume of distribution (Vd) of VRC07-523LS, PGDM1400LS, and PGT121.414.LS | At Days 1, 4, 7, 29, 57, 169, 225 and 337 |
| Terminal elimination rate constant (λz) of VRC07-523LS, PGDM1400LS, and PGT121.414.LS | At Days 1, 4, 7, 29, 57, 169, 225 and 337 |
| Terminal half-life (T1/2) of VRC07-523LS, PGDM1400LS, and PGT121.414.LS | At Days 1, 4, 7, 29, 57, 169, 225 and 337 |
| Area under the magnitude-breadth curve (AUC-MB) of VRC07-523LS, PGDM1400LS, and PGT121.414.LS | At Days 1, 4, 7, 29, 57, 169, 225 and 337 |
| Presence of antidrug antibodies (ADAs) for VRC07-523LS, PGDM1400LS, and PGT121.414.LS | At Days 1, 169 and 337 |
Countries
Brazil, Peru, United States
Outcome results
None listed